The Effect of Intravitreal Bevacizumab as a Pretreatment of Vitrectomy for Diabetic Vitreous Hemorrhage on Recurrent Hemorrhage

References

• de Bustros S, Glaser BM, Johnson MA. Thrombin infusion for the control of intraocular bleeding during vitreous surgery. Arch Ophthalmol 1985;103(6):837–839
   Google Scholar
• de Bustros S, Glaser BM, Michels RG, Auer C. Effect of epsilon-aminocaproic acid on postvitrectomy hemorrhage. Arch Ophthalmol 1985;103(2):219–221
   Google Scholar
• Ramezani AR, Ahmadieh H, Ghaseminejad AK, et al. Effect of tranexamic acid on eary postvitrectomy diabetic hemorrhage: A randomised clinical trial. Br J Ophthalmol 2005;89(8):1041–1044
   Google Scholar
• Liggett PE, Lean JS, Barlow WE, Ryan SC. Intraoperative argon endophotocoagulation for recurrent vitreous hemorrhage after vitrectomy for diabetic retinopathy. Am J Ophthalmol 1987;103(2):146–149
   Google Scholar
• Joondeph BC, Blankenship GW. Hemostatic effects of air versus fluid in diabetic vitrectomy. Ophthalmology 1989;96(12):1701–1706
   Google Scholar
• Koutsandrea CN, Apostolopoulos MN, Chatzouil DZ, et al. Hemostatic effects of SF6 after diabetic vitrectomy for vitreous hemorrhage. Acta Ophthalmol Scand 2001;79(1):34–38
   Google Scholar
• Yang CM, Yeh PT, Yang CH. Intravitreal long-acting gas in the prevention of early postoperative vitreous hemorrhage in diabetic vitrectomy. Ophthalmology 2007;114(4):710–715
   PubMed Web of Science ®Google Scholar
• Bodanowitz S, Kir N, Hesse L. Silicone oil for recurrent vitreous hemorrhage in previously vitrectomized diabetic eyes. Ophthalmologica 1997;211(4):219–222
   Google Scholar
• Packer AJ, McCuen BJ, Hutton WL, Ramsay RC. Procoagulant effect of intraocular sodium hyaluronate after phakic diabetic vitrectomy: A prospective randomized study. Ophthalmology 1989;96(10):1491–1494
   Google Scholar
• Faghihi H, Taheri A, Farahvash MS, et al. Intravitreal triamcinolon acetonide injection at the end of vitrectomy for diabetic vitreous hemorrhage: A randomized, clinical trial. Retina 2008;28(9):1241–1246
   Google Scholar
• Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: Bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 2007;12(3):356–361
   PubMed Web of Science ®Google Scholar
• Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113(3):363–372
   PubMed Web of Science ®Google Scholar
• Bressler NM. Antiangiogenic approaches to age-related macular degeneration today. Ophthalmology 2009;116(10 suppl):15–23
   Google Scholar
• Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007;114(10):1860–1867
   Google Scholar
• Soliman W, Vinten M, Sander B, et al. Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema. Acta Ophthalmol 2008;86:365–371
   PubMed Web of Science ®Google Scholar
• Hoeh AE, Ach T, Schaal KB, et al. Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2009;247:1635–1641
   PubMed Web of Science ®Google Scholar
• Ehrlich R, Ciulla TA, Moss AM, Harris A. Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion: 6 months of follow-up. Graefes Arch Clin Exp Ophthalmol 2010;248:375–380
   Google Scholar
• Hsu J, Kaiser RS, Sivalingam A, et al. Intravitreal bevacizumab (avastin) in central retinal vein occlusion. Retina 2007;27(8):1013–1019
   PubMed Web of Science ®Google Scholar
• Lo WR, Kim SJ, Aaberg TM Sr, et al. Visual outcomes and ıncidence of recurrent vitreous hemorrhage after vitrectomy in diabetic eyes pretreated with bevacizumab (Avastin). Retina 2009;29(7):926–931
   Google Scholar
• Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 2006;26(6):699–700
   PubMedGoogle Scholar
• Rizzo S, Genovesi-Ebert F, Di Bartolo E, et al. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol 2008;246(6):837–842
   Google Scholar
• Yang CM, Yeh PT, Yang CH, Chen MS. Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy. Am J Ophthalmol 2008;146(2):211–217
   PubMed Web of Science ®Google Scholar
• Ishikawa K, Honda S, Tsukahara Y, Negi A. Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye (Lond) 2009;23(1):108–111
   PubMed Web of Science ®Google Scholar
• Modarres M, Nazari H, Falavarjani KG, et al. Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy. Eur J Ophthalmol 2009;19(5):848–852
   Google Scholar
• The Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision: Clinical application of results of a randomized trial Report 4. Ophthalmology 1988;95:1321–1334
   Google Scholar
• Franzco JY, Frcophth CW, Franzco PA, Franzco RB. Avastin as an adjunt to vitrectomy in the management of severe proliferative diabetic retinopathy: Aprospective case series. Clinical and Experimental Ophthalmology 2008;36:449–454
   Google Scholar
• Arevola JF, Maia M, Flynn HW Jr, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmology 2008;92:213–216
   Google Scholar
• Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855–859
   PubMed Web of Science ®Google Scholar